Is CP therapy a therapeutic option for severe COVID-19
infection?
CP therapy for COVID-19 treatment has yielded promising results. For
example, in a trial of 10 severe COVID-19 patients,191CP therapy was well tolerated and improved the clinical outcomes. The
viral load was undetectable after CP transfusion in 7 patients who had
viremia. No severe adverse effects were observed. Other clinical trials
have shown the beneficial effect of CP therapy in COVID-19 patients and
ongoing clinical trials will provide additional data on its efficacy,
safety and optimal timing for treatment (Table 2 ). In this
regard, it is unclear whether in patients with a high viral load, such
as severely ill patients, CP therapy may drive tissue pathology through
immune complexes or complement activation.